[
    [
        {
            "time": "",
            "original_text": "天坛生物所属企业获得阿联酋药物临床试验批件",
            "features": {
                "keywords": [
                    "天坛生物",
                    "阿联酋",
                    "临床试验",
                    "批件"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物所属企业获得阿联酋药物临床试验批件",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "天坛生物(600161.SH)：武汉血制获阿联酋同意开展“静注COVID-19人免疫球蛋白(pH4)”临床试验",
            "features": {
                "keywords": [
                    "天坛生物",
                    "武汉血制",
                    "阿联酋",
                    "静注COVID-19人免疫球蛋白",
                    "临床试验"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物(600161.SH)：武汉血制获阿联酋同意开展“静注COVID-19人免疫球蛋白(pH4)”临床试验",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "天坛生物(600161.SH)：获阿联酋批准武汉血制开展“静注COVID-19人免疫球蛋白(pH4)”临床试验",
            "features": {
                "keywords": [
                    "天坛生物",
                    "武汉血制",
                    "阿联酋",
                    "静注COVID-19人免疫球蛋白",
                    "临床试验"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物(600161.SH)：获阿联酋批准武汉血制开展“静注COVID-19人免疫球蛋白(pH4)”临床试验",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "天坛生物：静脉COVID-19人免疫球蛋白（pH4）临床试验获批",
            "features": {
                "keywords": [
                    "天坛生物",
                    "静脉COVID-19人免疫球蛋白",
                    "临床试验",
                    "获批"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物：静脉COVID-19人免疫球蛋白（pH4）临床试验获批",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "天坛生物：血液制品目前共计拥有白蛋白、免疫球蛋白、凝血因子等三大类、14个品种、72个产品生产文号",
            "features": {
                "keywords": [
                    "天坛生物",
                    "血液制品",
                    "白蛋白",
                    "免疫球蛋白",
                    "凝血因子"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天坛生物：血液制品目前共计拥有白蛋白、免疫球蛋白、凝血因子等三大类、14个品种、72个产品生产文号",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "天坛生物：目前公司在营单采血浆站（含分站）数量达55家",
            "features": {
                "keywords": [
                    "天坛生物",
                    "单采血浆站",
                    "数量",
                    "55家"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天坛生物：目前公司在营单采血浆站（含分站）数量达55家",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        }
    ]
]